Anbio Biotechnology Class A Ordinary Shares (NNNN)

Anbio Biotechnology Class A Ordinary Shares at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Anbio Biotechnology Class A Ordinary Shares (NNNN) is a Medical - Instruments & Supplies company based in DE with a market capitalization of $1.5B. Revenue grew 19.2% year-over-year and free cash flow was negative at -$6.7M. This page tracks NNNN's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

DE · 27 employees · IPO Feb 19, 2025

Valuation

Valuation & price

$26.94as of May 17, 2026· -48.3% vs 52w high

163.6

P/E ratio

Latest-FY diluted EPS

49.53

P/B ratio

Market cap ÷ book equity

Dividend yield

Price — last 12 months

$52.10$32.40$12.70Jul 25Dec 25Jul 26
$12.2952-week range$52.10
Loading valuation history…

Fundamentals

Key fundamentals

$1.5B

Market cap

19.2%

Revenue growth (YoY)

87.2%

Gross margin

-$6.7M

Free cash flow (USD)

-$11.9M

Net debt

Net cash position

3.8%

Share dilution

2/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

20212025

$4.4M$9.8M

Free cash flow by year

20212025

$4.2M-$6.7M

Gross margin by year

20212025

57.4%87.2%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 20-F/A filed Apr 9, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 6-K filingMay 19, 2026Filing

    Amended Articles of Association

  • 6-K filingApr 27, 2026Filing

    Amended Articles of Association

  • Annual reportApr 9, 2026Filing

    20-F Filed

  • Annual reportApr 7, 2026Filing

    20-F Filed

Questions

Frequently asked questions

What is Anbio Biotechnology Class A Ordinary Shares's market cap?

Anbio Biotechnology Class A Ordinary Shares (NNNN) has a market capitalization of $1.5B.

What is NNNN's P/E ratio?

NNNN trades at a price-to-earnings ratio of 163.6, based on its latest fiscal-year diluted earnings per share and the most recent cached price.

What is NNNN's price-to-book (P/B) ratio?

NNNN trades at 49.53 times book value per share.

Are insiders buying NNNN stock?

SEC Form 4 filings show no open-market insider buys at Anbio Biotechnology Class A Ordinary Shares in the last 90 days (0 sells).

Same arena

Related companies in Medical - Instruments & Supplies

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.